IntegenX Scores $40M to Commercialize DNA Identification System
RapidHIT 200 is a biometric system that allows analysis at the point of collection.!--h2>
IntegenX secured $40 Million in Series C funding. The company plans on using the money to accelerate development of its product pipeline and to commercialize the RapidHIT™ 200 Human Identification System.
The RapidHIT 200 is a sample-to-profile biometric system. The system is reportedly the first fully automated DNA identification technology capable of producing DNA profiles from buccal swabs or other human samples in less than 90 minutes.
The RapidHIT 200 allows DNA analysis at the point of collection. Thus it is expected to enable law enforcement, government agencies, and forensic laboratories to conduct real-time human DNA analysis.
By contrast, human DNA samples currently must be transported or shipped to laboratories that rely on highly trained technicians using multiple instruments for analyses taking 10 to 14 hours. The RapidHIT 200 and consumables system is expected to launch in the U.S. and abroad through the first six months of 2012.
New investor Essex Woodlands led the financing round and joins existing investors Domain Associates, QuestMark Partners, Greenspring Associates, Cross Creek Capital, RONAholdings LLC, Samsung Ventures, and strategic partner In-Q-Tel.
IntegenX also commercializes the Apollo 324, an automated DNA and RNA library preparation platform for next-generation sequencing. The system can prep up to 32 libraries per day, the firm says. It also offers a selection of optimized platform-specific library preparation reagent kits. IntegenX’ GenTegra™ and GenPlate® products stabilize DNA, RNA, whole blood, and biological fluids, allowing dry-state room temperature storage.